viernes, 20 de diciembre de 2024

Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t an Option

https://www.cancer.gov/news-events/cancer-currents-blog/2024/head-neck-cancer-cetuximab-versus-durvalumab?cid=eb_govdel

No hay comentarios:

Publicar un comentario